Schizophrenia Research
Volume 76, Issue 2 , Pages 267-272 , 15 July 2005

The crossover approach to switching antipsychotics: What is the evidence?

  • Gary Remington

      Affiliations

    • Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    • Corresponding Author InformationCorresponding author. Tel.: +1 416 535 8501Ext.4750; fax: +1 416 979 4292.
    • ,
  • Pierre Chue

      Affiliations

    • Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Emmanuel Stip

      Affiliations

    • Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Lili Kopala

      Affiliations

    • Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Todd Girard

      Affiliations

    • Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    • ,
  • Bruce Christensen

      Affiliations

    • Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8

Received 2 September 2004 ,Revised 13 January 2005 ,Accepted 18 January 2005.

References 

  1. Beauchemin MA, Millaud F, Nguyen KA. A case of neuroleptic malignant syndrome with clozapine and risperidone. Can. J. Psychiatry. 2002;47:886
  2. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 1990;16:551–561
  3. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology. 2003;166:391–399
  4. Chong SA, Tan CH, Lee HS. Atrial ectopics with clozapine–risperidone combination. J. Clin. Psychopharmacol. 1997;17:130–131
  5. Cohen J. Statistical power analysis for the behavioral sciences. third ed.. Hillsdale: Erlbaum; 1988;
  6. Fleischhacker WW, Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs. 1997;53:915–929
  7. Flynn SW, Altman S, MacEwan GW, Blake LL, Greenridge LL, Honer WG. Prolongation of clozapine-induced granulocytopenia associated with olanzapine. J. Clin. Psychopharmacol. 1997;17:494–495
  8. Gardos G. Are antipsychotic drugs interchangeable?. J. Nerv. Ment. Dis. 1974;159:343–348
  9. Godleski LS, Sernyak MJ. Agranulocytosis after addition of risperidone to clozapine treatment. Am. J. Psychiatry. 1996;153:735–736
  10. Howell D. Statistical methods for psychology. third ed.. Belmont: Duxbury Press; 1992;
  11. Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J. Clin. Psychiatry. 2000;61:833–840
  12. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, Christodoulou GW. Toxic interaction between risperidone and clozapine: a case report. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 2002;26:407–409
  13. Lee CT, Conde BJ, Mazlan M, Visanuyothin T, Wang A, Wong MM, et al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J. Clin. Psychiatry. 2002;63:569–576
  14. Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am. J. Psychiatry. 2002;159:1534–1540
  15. Masand PS, Berry SL. Switching antipsychotic therapies. Ann. Pharmacother. 2000;34:200–207
  16. Remington G, Kapur S. A typical antipsychotics: are some more atypical than others?. Psychopharmacology. 2000;148:3–15
  17. Rosenthal R. Science and ethics in conducting, analyzing, and reporting psychological research. Psychol. Sci. 1994;5:127–134
  18. Rosenthal R, DiMatteo MR. Meta-analysis: recent developments in quantitative methods for literature reviews. Annu. Rev. Psychol. 2001;52:59–82
  19. Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J. Psychiatry Neurosci. 2000;25:137–153
  20. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J. Clin. Psychiatry. 1997;58:63–72
  21. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J. Clin. Psychiatry. 2003;64:580–588

PII: S0920-9964(05)00048-4

doi: 10.1016/j.schres.2005.01.009

Schizophrenia Research
Volume 76, Issue 2 , Pages 267-272 , 15 July 2005

Article Tools

* Image Usage & Resolution